Finoriq research workspace
BioAge Labs, Inc. (BIOA) SEC Filings & Filing Highlights
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product. Review BIOA SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
- Company
- BioAge Labs, Inc. (BIOA)
- Ticker
- BIOA
- Market Cap
- $999.7M
- Latest Price
- $22.49
- Industry
- Biotech & Pharma
BioAge Labs, Inc. (BIOA) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for BioAge Labs, Inc. (BIOA).
| Event | Form | Date |
|---|---|---|
| On June 10, 2026, BioAge Labs, Inc. held its 2026 Annual Meeting of Stockholders and the Compan...On June 10, 2026, BioAge Labs, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders and the Company’s stockholders voted on an... | 8-K5.07 | 2026-06-12 |
| BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business UpdatesBioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates | 8-K2.02 | 2026-05-08 |
| BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fou...BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025 | 8-K7.01 | 2026-03-24 |
| BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fou...BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025 | 8-K2.02 | 2026-03-24 |
| BioAge Announces Pricing of Upsized $115.0 Million Public OfferingBioAge Announces Pricing of Upsized $115.0 Million Public Offering | 8-K7.01 | 2026-01-22 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.